LDVP Regimen Following Radiotherapy Effective for Stage III/IV T-Cell Lymphoma
the Cancer Therapy Advisor take:
Extranodal natural killer/ T cell lymphoma (ENKL) is a rare, but aggressive type of non-Hodgkin lymphoma that is known to have a poor response and survival rate.
Although radiotherapy is known to be highly effective in the treatment of ENKL, there is no standard chemotherapeutic regimen for the treatment of advanced-stage ENKL. Investigators hypothesized that patients who complete a full course of chemotherapy can reduce the size of the cancer, and following it with radiotherapy, may prove to be effective in controlling ENKL.
The investigators conducted a study to determine the safety and efficacy of a chemotherapy regimen of L-asparaginase, etoposide, dexamethasone, and cisplatin (LVDP), followed by regional radiotherapy, for the treatment of newly diagnosed patients with stage III/IV ENKL.
The efficacy was determined by observing the overall response rate (ORR), overall survival (OS) and progression-free survival (PFS) at 1 or 2 years.
A total of 18 patients were in the study, and all patients received an average of 4.04 cycles of chemotherapy. The study results revealed that the ORR was 50%, and at the 1-year follow-up, the OS and PFS rates were 72.2% and 50.0%, respectively, and at the 2-year follow-up, the OS and PFS rates were 33.3% and 22.2%, respectively; the median OS was 23.0 months and PFS was 10.5 months. In terms of safety endpoints, the most common adverse event was bone marrow suppression.
The authors concluded that LVDP regimen in combination with radiotherapy was effective in the treatment for late ENKL and improved survival; however, larger, prospective studies should be conducted to validate the efficacy of the regimen in patients with advanced-stage ENKL.
Extranodal natural killer/ T cell lymphoma (ENKL) is a rare, but aggressive type of non-Hodgkin lymphoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Plastics and Cancer
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer